SAN FRANCISCO and HERZLIYA, Israel, Nov. 11, 2019 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced that two posters related to its investigational therapy, BIO89-100, will be presented today at The Liver Meeting 2019, the annual meeting of the American Association for the Study of Liver Diseases (AASLD), taking place November 8-12, in Boston, Massachusetts. BIO89-100 is a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21) in clinical development for the treatment of nonalcoholic steatohepatitis (NASH).
The poster presentations will include results from the Phase 1a clinical trial in healthy volunteers demonstrating that BIO89-100 was generally well tolerated at single doses up to 78 mg with a generally dose-proportional pharmacokinetic profile allowing for a weekly or every two-week dosing. BIO89-100 also was associated with robust and clinically significant improvements versus baseline in triglycerides, LDL-C, HDL-C and adiponectin in this study. A second poster presentation of preclinical data demonstrated the positive effect of BIO89-100 in reducing preference for sweetened water in obese monkeys will also be presented.Poster PresentationsAbstract Number: 2138
Presentation Title: BIO89-100, a Novel GlycoPEGylated FGF21 Analogue Demonstrates Robust Reduction in Serum Lipids and Long Half-Life in a Phase 1 Randomized, Controlled Single Ascending Dose Trial in Healthy Subjects
Session Title: NAFLD and NASH Therapeutics: Pharmacologic and Other
Presenting Author: Dr. Rohit Loomba, Director, NAFLD Research Center, Professor of Medicine, University of California at San Diego
Session Time: Monday, Nov 11 at 8 AM
Location: Hynes Convention Center, Hall B
Bay Street News